Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab.

导出 LinkOut

翻译打印收藏纠错

作者： Neel I,Nissen ^[1] ; Stephanie,Kehlet ^[2] ; Mogens K,Boisen ^[3] ; Maria,Liljefors ^[4] ; Christina,Jensen ^[2] ; Astrid Z,Johansen ^[3] ; Julia S,Johansen ^[5] ; Janine T,Erler ^[6] ; Morten,Karsdal ^[2] ; Joachim H,Mortensen ^[2] ; Anette,Høye ^[6] ; Nicholas,Willumsen ^[2]

作者单位： Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark. nin@nordicbio.com.;Biomarkers and Research, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark. nin@nordicbio.com. ^[1] Biomarkers and Research, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark. ^[2] Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark. ^[3] Department of Clinical Science, Intervention and Technology, Karolinska University Hospital Huddinge, Stockholm, Sweden. ^[4] Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.;Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ^[5] Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark. ^[6]